Murali Mallem

Murali Mallem has a diverse work experience in the pharmaceutical and biotechnology industry. Murali is currently working at Entrada Therapeutics, where they hold the position of Vice President and Head of CMC since July 2022. Prior to this role, they served as the Head of CMC from June 2019 to June 2022 at the same company.

Before joining Entrada Therapeutics, Murali worked at Bristol-Myers Squibb as a Matrix Team Lead from July 2016 to June 2019. Murali was responsible for leading cross-functional teams in the company.

Murali also had a role at Shire as a Senior Bioengineer II from April 2014 to July 2016. Murali'swork focused on bioengineering in the company.

Murali started their career at Merck in 2007, where they held various roles. Murali was an Associate Principal Scientist from June 2012 to April 2014. Prior to that, they served as a Senior Research Biochemical Engineer from October 2010 to May 2012 and as a Research Biochemical Engineer from August 2007 to September 2010.

Murali'searliest work experience was at Lonza, where they worked as a Process Development Associate from September 2005 to August 2007.

Overall, Murali Mallem has gained significant expertise and leadership experience in the CMC field through their various roles in reputable companies such as Entrada Therapeutics, Bristol-Myers Squibb, Shire, Merck, and Lonza.

Murali Mallem has pursued education in the field of management, chemical engineering, and chemical engineering at different institutions. Murali holds a Master of Science (MS) degree in Management from Emmanuel College in Boston. Additionally, they pursued a Master of Science (MS) degree in Chemical Engineering from South Dakota Mines. Murali Mallem also obtained a Bachelor of Technology (B.Tech) degree in Chemical Engineering from Jawaharlal Nehru Technological University.